Several factors support TNBC as a good candidate for immunotherapy, including the high presence of tumor‐infiltrating immune cells, the generation of neoantigens due to the tumor's mutational load, and the high expression of PD‐1 and PD‐L1 (70% and 59% of cases, respectively, in TNBC). The gene discussed is PDCD1; the disease is neoplasm.